The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27 KIP1 expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.
Introduction PTEN (phosphatase and tensin homologue deleted in chromosome 10) is a tumour suppressor gene located on chromosome 10q23 (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000) . Somatic deletions or mutations have been identified in a variety of cancers, including glioblastomas, metastatic prostate cancers, lung, breast and endometrial cancers and malignant melanoma, making it one of the most commonly mutated genes in human cancers together with p53. Germline mutations lead to Cowden disease, BannayanZonana syndrome or Lhermitte-Duclos disease, all characterized by the development of multiple benign tumours and a predisposition to malignancies (Marsh et al., 1998) . Mice heterozygous for PTENinactivating mutations also have a high incidence of spontaneous tumours of various histological origins (Di Cristofano et al., 1999) . Complete inactivation of the gene is embryonic lethal (Di Cristofano et al., 1998) .
PTEN acts as a lipid phosphatase catalysing the removal of phosphates specifically from the D3 position of phosphoinositides, thereby opposing the activity of phosphoinositide 3-kinase (PI3K) (Maehama and Dixon, 1998) . Activated PI3K catalyses the accumulation of phosphatidylinositol-3,4-bisphosphate (PI-3,4-P 2 ) and phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P 3 ) in the plasma membrane, and thereby modulates the activity of downstream pleckstrin homology domain-containing signalling molecules, among them Akt/PKB, an important survival factor. Akt becomes activated by phosphorylation in response to membrane translocation (Ward and Cantrell, 2001) , activating proliferative and antiapoptotic signalling pathways. The primary tumour suppressive activity of PTEN comes from blocking this pathway by maintaining low basal levels of PI-3,4,5-P 3 . Restoration of PTEN expression to PTEN-null tumour cell lines markedly reduces proliferation rates, as a consequence of cell cycle arrest and increased apoptosis. These effects of PTEN are readily reversed by expression of constitutively activated Akt (Furnari et al., 1998; Li and Sun, 1998; Cheney et al., 1999; Davies et al., 1999; Lu et al., 1999) .
The role of the relative balance of activities of PI3K and PTEN in regulating T-cell survival and growth has only just begun to be investigated. In mice, the inactivation of one PTEN allele is sufficient to promote inappropriate lymphocyte survival and proliferation, leading to the development of a fatal autoimmune syndrome (Di Cristofano et al., 1999) . Furthermore, mice engineered such that PTEN is selectively absent from developing T cells present with an increased total number of T cells. These cells are hyperproliferative, and exhibit no significant difference in the spontaneous rate of apoptosis, even though they are resistant to apoptosis induced by withdrawal of trophic factors (Suzuki et al., 2001) . T cells from these mice are spontaneously activated, and constitutively express hyperphosphorylated Akt. Notably, these animals all develop malignant T-cell lymphomas by 17 weeks of age, indicating that disruption of the balance between PI3K and PTEN activities can contribute to oncogenesis in T cells.
The Jurkat T-cell line (an acute lymphocytic leukaemia) has been shown to be PTEN-null (Sakai et al., 1998; Shan et al., 2000; Xu et al., 2002) , making it a useful model system for studying the role of PTEN in normal and leukaemic T-cell biology. Recently, PTEN was shown to inhibit proliferation in Jurkat T cells without inducing cell cycle arrest (Xu et al., 2002) . In this study, we expand upon these observations by directly testing the role of apoptosis in the PTENinduced proliferative slowing. Finding no role for increased apoptosis or cell cycle arrest in these cells, we found instead that PTEN has a pronounced, uniform effect on the rate of progression throughout each phase of the cell cycle. This results in markedly slower cell division without altering the percentage of cells present in any given phase of the cell cycle.
These changes correlate with alterations in the expression level and activity of multiple proteins involved in cell cycle control. The ability of PTEN to uniformly regulate progression throughout the entire cell cycle, without initiating arrest at either the G1 or G2 checkpoints represents a previously unappreciated mode of action for PTEN.
Results

Generation of PTEN-inducible Tet-On Jurkat T-Cell Lines
To assess the phenotypic effects of restored PTEN expression in a PTEN-null haematopoietic tumour, PTEN cDNA was placed under tetracycline-inducible expression in the leukaemic T-cell line Jurkat, which has previously been shown to be PTEN-null (Sakai et al., 1998; Shan et al., 2000; Xu et al., 2002) . Two independent clones, PIJ (PTEN-Inducible Jurkat)-12 and PIJ-17, were further analysed for PTEN induction upon dox treatment, and compared to a non-PTENexpressing control clone, Con18 (Figure 1a ). Both PIJ-12 and PIJ-17 gave similar responses in all assays, and were used interchangeably throughout these studies. PTEN levels increased in PIJ cells in a dose-dependent manner in response to dox (Figures 1b and 2c) . PTEN expression was rapid and persistent, being detectable as early as 4 h after dox induction and reaching a peak between 24 and 48 h after induction (Figure 1c, top panel) . PTEN expression inversely correlated with phosphorylation of Akt, indicating that the PTEN is functional (Figure 1c, bottom panel) .
PTEN expression inhibits Jurkat T-Cell proliferation
To study the effect of PTEN expression on Jurkat T-cell proliferation, PIJ-12, PIJ-17 and Con18 cells were treated with dox, and the total number of cells remaining in culture were assessed every 24 h. Both PIJ-12 and PIJ-17 cells showed a dramatic decline in proliferation in response to dox treatment and the induction of PTEN expression, while proliferation in Con18 cells was unaffected by dox ( Figure 2) . The growth inhibitory effect of dox on PIJ cells was dosedependent, as seen in Figure 2b . Although the trend was not uniform at all dox doses, the general trend clearly indicates a dose-dependency. Notably, the absence of a demonstrable difference in proliferation between cells treated with 100 and 300 ng/ml of dox was not a consistent observation. The effect of dox on proliferation correlated overall with the level of induced PTEN expression and decreased Akt-Ser-473 phosphorylation (Figure 2c and d) .
In an effort to corroborate these findings, we transiently transfected PTEN into the CEM T-cell line. CEM cells, similar to Jurkat cells, are derived from an acute lymphocytic leukaemia and are known to have a deletion in exons 2-5 of the PTEN gene (Sakai et al., 1998) . This deletion corresponds to the phosphatase domain of PTEN and renders the protein unstable (Georgescu et al., 1999) . PTEN expression in CEM cells also reduced their proliferation rate, although this effect was slightly delayed compared to Jurkat cells (data not shown).
PTEN expression in Jurkat T cells only marginally increases apoptosis
Given the previously established role of PTEN expression in inducing apoptosis when expressed in PTEN-null (Cheney et al., 1999; Davies et al., 1999; Xu et al., 2002) , we tested whether the antiproliferative effect of PTEN could be due to increased apoptosis. In order to assess this possibility, changes in the spontaneous rate of cell death were determined. Fragmentation of genomic DNA, a hallmark of apoptotic death, was measured by TUNEL at 24 h intervals up to 120 h (Gold et al., 1993) . While a statistically significant increase in the percentage of TUNEL-positive cells was not observed at any of the time points investigated, there was a trend towards a marginal increase in the percentage of TUNEL-positive cells in the PIJ cells, but not in the Con18 cells upon dox induction (Figure 3a and data not shown). Etoposide, a classical inducer of apoptosis, greatly increased the percentage of TUNELpositive cells, validating the assay (Figure 3a) . Furthermore, analysis of cell viability by flow cytometry of synchronized cell populations (G1-and G2-enriched fractions isolated by elutriation) also showed no appreciable dox-induced changes in cell death at any time point between 24 and 120 h (data not shown). In order to test if PTEN expression was stimulating appreciable nonapoptotic cell death, cell death due to necrosis was assessed by measuring the loss of cell membrane integrity, as indicated by the release of LDH into the culture supernatant (Decker and LohmannMatthes, 1988) . No PTEN-dependent increases in LDH release could be detected following 24-120 h of PTEN induction (Figure 3b ). The addition of the detergent Triton X-100, however, resulted in rapid release of LDH into the medium. The results from the LDH assay are also consistent with our results from trypan blue exclusion assays, in which the percentage of trypan blue-positive cells was never observed to be significantly different in Jurkat or CEM PTEN-null and PTENexpressing cells, and never rose above 5-10% of total cells (data not shown). Together, these data argue against PTEN having a substantial effect on the rate of spontaneous cell death in Jurkat T cells within the timeframe in which PTEN reduces the cellular proliferation rate.
Since activation of effector caspases is an obligate step in apoptosis, we assessed the ability of ZVAD-FMK, a broad-spectrum peptidic inhibitor of the effector caspases involved in mediating apoptotic signals (Genestier et al., 1998) , to reverse the antiproliferative effect of PTEN expression in these cells. The addition of ZVAD-FMK at 50 mm had no effect upon the ability of PTEN to inhibit Jurkat or CEM T-cell proliferation ( Figure 3c and data not shown). However, this concentration of ZVAD-FMK completely blocked caspase 3 activation in response to anti-Fas antibody, indicating that this concentration of peptide was effective in blocking the effector caspase cascade in these cells (Figure 3d ). Consistent with our TUNEL data, there was a small, but reproducible, increase in caspase 3 activity associated with PTEN expression in Jurkat T cells, which was completely blocked by ZVAD-FMK ( Figure 3d ). That increased caspase 3 activity need not necessarily lead to substantial increases in apoptosis in T cells has been demonstrated previously (Alam et al., 1999) . These results further confirm that the small amount of PTENinduced apoptosis seen in PTEN-expressing Jurkat and CEM T cells did not substantially contribute to the slower proliferation rates. Several studies have shown that reintroduction of PTEN into nonhaematopoietic PTEN-null tumour cells leads to arrest in the G1 phase of the cell cycle (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000; Leslie and Downes, 2002) . In contrast to these previous studies, the percentage of cells present within the different stages of the cell cycle was largely unaffected by PTEN expression in Jurkat T cells (Figure 4a ). These results are in accordance with the recently published data by Xu et al. (2002) . On this basis, Xu et al. concluded that the antiproliferative effects of PTEN are not due to changes in cell cycle progression. Alternatively, the static cell cycle pattern could result from delayed progression throughout the cell cycle, as reported for flies mutant in p70 S6 K , a downstream target of PTEN (Montagne et al., 1999) . Such an effect would manifest as a slower rate of cell division, with no change in the static DNA profile of the cells. To test if PTEN expression in Jurkat T cells causes slowed cell division, PIJ-17 and Con18 cells were pulse-labelled with 5(6)-carboxyfiuorescein diacetate succinyl ester (CFDA-SE) prior to induction of PTEN expression. In the absence of dox induction, both cell lines showed the characteristic decline in CFDA-SE fluorescence that is indicative of cell division ( Figure 5 ). However, the degree of the shift was retarded in doxtreated PIJ-17 cells compared to control cells. The delay in the leftward shift associated with proliferation was seen as early as day 2 (not shown) and was pronounced by day 5. Thus, the PTEN-expressing Jurkat T cells continued to divide, albeit at a slower rate than PTENnull cells.
To confirm that the primary antiproliferative effect of PTEN expression in Jurkat T cells is due to delayed cell cycle progression, cell cycle passage was measured in a BrdU pulse-chase experiment. PTEN expressing cells progressed through the cell cycle without apparent arrest at any stage. However, the percentage of cells entering and exiting G1 indicates that PTEN exerts a global inhibitory effect on the rate of cell cycle progression (Figure 6a) . The rate at which BrdU positive cells progress into G1 (G1 entry) provides an indication of the rate of transit through late S, G2 and M. PTEN-expressing cells consistently entered G1 more slowly than control cells (Figure 6a , left panel). Likewise, the rate at which BrdU negative cells become depleted from the G1 pool (G1 exit) indicates the transit rate through G1. PTEN-expressing cells were substantially delayed in exiting G1 (Figure 6a , middle panel). This is especially noticeable at later time points (10 h). Similarly, an estimation of the relative time required to complete the S phase is provided by the rate at which BrdU positive cells are depleted from the S phase pool (S exit). PTEN-expressing cells also showed a markedly delayed exit from S phase (Figure 6a, right  panel) .
In a second approach to this question, cells were arrested in the G2 phase of the cell cycle with the late G2 blocker SK&F 96365 following treatment with dox. Cells were released from G2 block and analysed by propidium iodide (PI) staining at various time points to assess the percentage of cells in each phase of the cell cycle. At later time points (10 h), more PTEN-expressing PIJ-17 cells remained in the G2/M phase than control cells (Figure 6b , left panel). This correlated with a reduced rate of entry into G1 (Figure 6b, middle panel) . The reduced rate of G1 entry in PTEN-expressing cells was most prominent shortly after release of the G2 block. Cells released from G2 arrest take longer to passage into G1 in the presence of PTEN. PTEN-expressing PIJ-17 cells are also delayed in exiting from G1 (10 h time point, Figure 6b , middle panel), which corresponds to delayed entry into S phase (Figure 6b, right panel) . These data were further corroborated in elutriation experiments in which cells separated into fractions enriched for either G1 or G2 phase, on the basis of cell size and DNA content, also demonstrated a slower passage through the cell cycle in PTEN-expressing cells (data not shown).
Thus, by these multiple measures, PTEN expression results in delayed progression through all stages of the cell cycle. The fact that the static DNA profile remains unchanged by PTEN expression indicates that the delay is proportional in all cell cycle stages. 
PTEN expression changes levels of cell cycle regulators
In order to elucidate the molecular mechanisms that may contribute to the effect of PTEN upon the rate of cell cycle progression, we carried out Northern blot analyses for a variety of cell cycle regulators. Examining unsynchronised cells, the levels of mRNAs encoding cyclins A, B1 and, to a lesser extent, B2 were reduced in PTEN-expressing Jurkat T cells (Figure 7a) . Levels of cyclin D2 mRNA, and to a lesser extent cyclin D3 mRNA, were decreased in PIJ-17 and PIJ-12 cells regardless of dox induction (Figure 7a ), suggesting that changes in the levels of these cyclins are not involved in the antiproliferative effects of PTEN in these cells. Cyclin D1 is not expressed in T cells and could not be detected in our Jurkat T cells (Ajchenbaum et al., 1993) . The mRNA levels of cdk4, the kinase partner of the D cyclins, were also markedly reduced upon PTEN expression in PIJ-12 and PIJ-17 cells (Figure 7a ). In addition to regulation by the cyclins, cdk4/6 and cdk2 are also subject to positive regulation by the phosphatase CDC25A, which also exhibited a PTEN-dependent reduction in message level in Jurkat T cells (Figure 7a) .
The cyclin-dependent kinase inhibitor p27 KIPl has also been reported to be elevated upon expression of PTEN in PTEN-null tumour lines, and is responsible for delayed progression and arrest in G1 in these cells (Cheney et al., 1999; Wu et al., 2000) . In our cells, the expression level of p27 KIP1 was substantially increased in PTEN-expressing cells following 48 h of dox induction (Figure 7b, upper panel) , consistent with the delayed progression through G1 noted above. Similar results were obtained using three different anti-p27 KIP1 blotting antibodies. ZAP-70 was blotted on the same membrane to confirm equal loading of protein on the gels (Figure 7b, lower panel) . Quantitation of the signal in a similar experiment revealed a 4.5-and 2.6-fold increase and a 5.7-fold decrease in expression upon dox treatment of PIJ-12, PIJ-17 and Con18 cells, respectively. The reason for the decrease in p27 KIP1 expression seen in the Con18 control cells is unclear.
Activated AKT rescues PTEN-induced reductions in cell proliferation
In order to test if the novel effects of PTEN expression upon Jurkat T cells are mediated by an unusual biochemical pathway, or by the same pathway that mediates the effects of PTEN upon cell cycle arrest and apoptosis in other cell lines, constitutively activated Akt was expressed in PIJ-17 and Con18 cells. Expression of active Akt in the dox-treated Con18 cells had only a marginal effect upon the rate of proliferation; however, Akt dramatically accelerated proliferation in dox-induced PIJ-17 cells, returning the rate of proliferation to that of a PTEN-null Jurkat T-cell line (Figure 8 ). These results indicate that PTEN slows cell cycle progression through the same biochemical pathways linked to cell cycle arrest or apoptosis in other systems. (2002)). Several studies have shown that introduction of PTEN into PTEN-null tumour cells has a variety of effects that may be cell or tissue specific. For example, PTEN expression in glioma cell lines, prostate cancer cell lines and endometrial carcinomas leads to G1 arrest alone (Furnari et al., 1998; Li and Sun, 1998; Cheney et al., 1999; Zhu et al., 2001; Davies et al., 2002) . In contrast, in breast cancer cell lines PTEN causes G1 arrest that is followed by apoptosis (Weng et al., 1999) . Moreover, in PTENnull thyroid cancer cell lines PTEN expression can generate G1 arrest alone or in combination with apoptosis (Weng et al., 2001b) . However, with the exception of a recent study by Xu et al. (2002) , none of these previous investigations have examined the role of PTEN in the transformed phenotype of haematological malignancies. In this study, we have used two PTENnull acute lymphocytic leukaemia cell lines, Jurkat and CEM, in order to address the effect of PTEN restoration upon the proliferation characteristics of leukaemic cells.
In contrast to what has been reported for solid tumours, expression of PTEN in these T-cell leukaemias, at levels sufficient to restore basal D3-phosphoinositide levels, neither caused cell cycle arrest nor stimulated significant increases in the rate of cell death, either by apoptosis or necrosis. Instead, PTEN expression slowed progression through all phases of the cell cycle, thereby reducing the rate of cell division, while maintaining a static DNA profile with the same percentage of cells in each phase of the cycle. This unusual mode of PTEN action has only been previously noted in PTEN-deficient neural stem/ progenitor cells, where PTEN-null cells proliferate faster and undergo more cell divisions during a given time period as compared to PTEN-expressing cells (Groszer et al., 2001) .
These results suggest that the importance of PTEN loss in the transformation of T lymphocytes may be largely independent of its antiapoptotic effects, and may instead be primarily related to its acceleration of the proliferation rate. Importantly, the PTEN-negative tumour cell lines that have been most extensively studied are derived from advanced cancers from tissues in which the cells are normally subject to anoikis, a specialized apoptotic pathway that becomes initiated when epithelial, endothelial and certain other cell types become detached from the extracellular matrix and/or neighbouring cells (Frisch and Screaton, 2001) . Anoikis is extremely sensitive to changes in the level of activated Akt, and consequently of PTEN levels (Lu et al., 1999; Yamada and Araki, 2001) , and protection from anoikis may be the primary force behind the high rate of inactivating PTEN mutations in many tumours. On the other hand, mature haematopoietic cells are not contact dependent and are not subject to anoikis. We speculate that, in cells that are not primed for apoptosis upon withdrawal of activated Akt (anoikis-insensitive cells), the ability of PTEN to uniformly delay progression throughout the cell cycle may represent the dominant mode of action of PTEN. Such a model, wherein PTEN expression has more of a modulatory function, would seem to make sense given that PTEN is known to be expressed in normal cells that are neither apoptotic nor arrested in G0 or G1, and is more in keeping with the effects that modulation of dPTEN expression has in Drosophila (Stocker and Hafen, 2000) .
It should be noted, however, that others have reported that overexpression of PTEN by transient transfection into Jurkat T cells can induce a strong apoptotic response in these cells (Wang et al., 2000) . We have also noticed this effect, albeit at substantially higher PTEN expression levels, which are associated with a profound overall inhibition of protein synthesis (MCS and RLW, unpublished observations). Xu et al., in a similar experimental system to that employed here, report increased cell death upon PTEN expression in their Jurkat T-cell line (Xu et al., 2002) . Most dramatically, they observe a linear increase in the number of trypan blue-positive cells over time. At 5 days after induction of PTEN expression, they find that approximately 50% of their PTEN-expressing cells fail to exclude trypan blue. We find no such accumulation of trypan blue-positive cells upon PTEN expression in either Jurkat or CEM cells, even up to 7 days following PTEN expression. The basis for this disparity remains to be determined; however, despite the large increase in trypan blue-positive cells observed by Xu et al. (2002) , the number of apoptotic cells never exceeded 3% of their total cells, which is consistent with the modest PTEN-inducible changes in the number of apoptotic cells that we report here. Although these authors correlate the decrease in proliferation with increased apoptosis in PTEN-expressing Jurkat cells, the ability of apoptotic blockade to reverse the effects of PTEN on proliferation was not tested. Here we show that in both Jurkat and CEM cells, treatment with a caspase inhibitor does not block the antiproliferative effect of PTEN. Thus indicating that the reduction in proliferation seen in PTEN-expressing cells is not due to increased apoptosis.
It should be noted, however, that we have not ruled out the possibility that PTEN expression may augment the rate of apoptosis at times later than those that we have investigated here, since it has been previously established that the effect of PTEN on apoptosis in the breast cancer cell line MCF-7 can substantially lag behind its effects on cell cycle (Weng et al., 1999) . Moreover, blocking PTEN-induced apoptosis in MCF-7 cells does not affect cell cycle distribution, an effect paralleled in our studies, and suggesting that the cells that undergo PTEN-induced apoptosis are not those that have altered cell cycle progression (Weng et al., 2001a) . Regardless, late-stage apoptosis, should it occur upon restored PTEN expression in PTEN-null leukaemic cells, is clearly not contributing to the slowed proliferation reported here at 48 and 72 h post-PTEN induction.
The precise mechanism by which PTEN expression in Jurkat T cells leads to proportionately delayed progression throughout the cell cycle remains to be determined; however, we show here that the increase in cycling time is associated with an increase in the level of p27 kipl protein, and a decrease in cyclin A, cyclin B, cdc25A and cdk4 transcripts. Cyclins A and B also show diminished protein expression levels (data not shown), while cdc25A and cdk4 have not yet been assessed at the protein level. Consistent with our p27 kip1 findings, prior studies showing PTEN-induced G1 arrest have also reported increased expression (Brennan et al., 1997; Cheney et al., 1999) . Furthermore, in primary human T cells activation of the PI3K/Akt pathway has been shown to downregulate p27 kip1 and induce cell cycle progression (Appleman et al., 2002) and p27 kipl deficient mice exhibit rapidly proliferating T cells (Zhang et al., 2000) . Thus, PTEN expression in Jurkat T cells coordinately acts on a variety of cell cycle regulatory proteins and on the rate of progression throughout the cell cycle. Interestingly, this mode of PTEN action is not being mediated by a novel signalling pathway, since an activated allele of Akt, an enzyme recognized to play a primary role in PTEN-induced apoptosis and cell cycle arrest pathways, also reverses the effect of PTEN on cell proliferation. Furthermore, we have shown that proliferation rates as well as Akt phosphorylation exhibit PTEN dose dependency. There is a clear general trend for decreased proliferation rate and decreased Akt phosphorylation with increasing PTEN levels. Experiments to more precisely delineate the mechanism by which PTEN increases cycling time in leukaemic T cells are presently underway.
In summary then, we find that while restoring PTEN expression in two T-cell leukaemia lines does, as expected, lead to reduced cellular proliferation, this is not a consequence of cell cycle arrest or increased cell death, which are the dominant modes of action for the antiproliferative effects of PTEN in solid tumours. Instead, in these leukaemic cells, PTEN exhibits an unusual mode of action, causing a proportional delay in progression through each phase of the cell cycle. We propose that these differences in modus operandi stem from differences in the overall cell physiology of the originating cell types (solid tissue cells vs blood cells), and may, in part, be reflective of differences in sensitivity to specialized cell death pathways, such as anoikis.
Materials and methods
Cell culture, antibodies and reagents
Jurkat (Tet-On) leukaemic T cells (Clontech Labs.) and CEM leukaemic T cells (ATCC) were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum (Clontech Tet-system approved FBS), 2 mm l-glutamine, 10 mg/ml ciprofloxacin. Polyclonal anti-human PTEN (clone 6H2.1) was obtained from Cascade Biosciences; polyclonal antiphosphoAkt (P-Ser472/473/474) from BD Biosciences; the three antip27 kipl Abs were obtained from Biosource (clone DCS-72.F6), BD Biosciences (clone G173-524), and a polyclonal antiserum from Cell Signaling; the anti-ZAP-70 antisera has been previously described (Wange et al., 1995) .
Generation of tetracycline-inducible PTEN-expressing Jurkat T cells and transient transfections
Stable and transient transfections were performed in Tet-On Jurkat cells and CEM cells by electroporation using a BTX (Genetronics Inc.) square wave electroporator (model ECM 830), set at 300 V for one 10-ms pulse. Cells were transfected with the linearized form of the response plasmid pTRE (Clontech) into which the wild-type human PTEN coding sequence was cloned in frame with an amino-terminal HA tag, or with the pTRE vector alone. All cells were also cotransfected with linearized pTK-Hyg (Clontech) to provide a selectable marker for pTRE-HA-PTEN transfectants. After 2 days, clones were selected by growth in medium supplemented with 400 mg/ml Hygromycin B and 1.5 mg/ml G418. Clonal lines were obtained by limiting dilution, resulting in the isolation of the non-PTEN-expressing control clone Con18 and the PTEN-expressing clones PIJ-12 and PIJ-17. The cell lines were maintained under drug selection with 100 mg/ml each of Hygromycin and G418. The pUSE(amp)-myr-Akt1 plasmid was purchased from Upstate Biotechnology, Inc.; the pTREFlag-PTEN was a kind gift of Dr Y Liu (Ohio State University).
Western blots
Cells were lysed with buffer supplemented with phosphatase inhibitors, as previously described (Shan et al., 2001) . Samples were separated in 4-12% Bis-Tris gels (Invitrogen Corp.) and transferred to nitrocellulose membranes. Proteins were detected by Western blot and enhanced chemiluminescence (Renaissance, NEN). In some experiments, Western blots were quantitated by scanning laser densitometry using NIH Image software.
Cell viability and cell cycle analysis
Cell viability was routinely measured by trypan blue exclusion under light microscopy and by flow cytometry (FACScalibur, Becton Dickinson). Cell proliferation was determined by counting total number of cells in culture. The density of the cells was maintained between 5 Â 10 5 and 7 Â 10 5 cells/ml by daily adjustment of culture volume. For cell cycle analysis by DNA content, 10 6 cells were washed twice in PBS, resuspended in 500 ml FBS and stored at À801C overnight. Cells were stained with a PI containing buffer, according to the NIM procedure, as described (Wersto and Stetler-Stevenson, 1995) . Cell cycle profiles were determined by flow cytometry and analysed using ModFit software (Allen, 1990 ).
Cell cycle analysis by BrdU pulse-chase and G2/M arrest For BrdU assays, we followed the protocol previously described by Wersto et al. (1998) . Briefly, 10 7 cells were labelled with 10 mm BrdU (Roche), for 20 min at 371C and visualized with an FITC-conjugated anti-BrdU antibody (clone B44, Becton Dickinson). The nuclei were stained with PI (10 mg/ml) for 60 min at r.t. and cells were analysed by flow cytometry. G2/M arrest was induced by the G2/M blocker SK&F 96365 (Calbiochem) (Nordstrom et al., 1992) . Cells were treated with or without dox for 24 h prior to addition of 5 mm SK&F for 18 h at 371C. DNA was stained with PI and cell cycle profiles were determined by flow cytometry as described above.
Apoptosis and cell death assays
Cells were treated with either dox or vehicle control before being harvested at varying time points. Caspase 3 activity (CaspACE Assay System, Promega Corp.) and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling (TUNEL) assay (In situ Cell Death Detection Kit, fluorescein; Roche) were performed in 10 6 cells following the manufacturer's protocol. Caspase 3 activity was normalized to total protein, measured by the BCA Protein Assay (Pierce). Total cell death (apoptosis and necrosis) was analysed by measuring levels of lactate dehydrogenase (LDH) in culture supernatants using a Cytotoxicity Detection kit (Roche).
Cell division determination
To determine the rate of cell division, cells were pulse-labelled with 1 mg/ml CFDA-SE (5(6)-carboxyfiuorescein diacetate succinyl ester) following the manufacturer's protocols (CFDA-SE Cell Tracer Kit, Molecular Probes). Proliferation was analysed by flow cytometry and cell generations were determined using ModFit software.
Treatment with ZVAD-FMK
Cells were treated with 50 mm of the caspase inhibitor ZVAD-FMK (Promega) for 30 min at 371C before dox or vehicle control was added. The medium was replaced at 24 h with fresh ZVAD-FMK and dox. An aliquot of cells was treated with 50 ng/ml of anti-Fas (clone CH-11, PanVera Corporation) for 16 h as a positive control. Total cell numbers were counted daily; caspase 3 activity was determined at 48 h as described above.
Northern blot analysis
Northern blot analysis was carried out as previously described (Gorospe et al., 1996) , using specific oligomer or cDNA probes. Oligomers complementary to mRNAs encoding human cdc25a (AGAATCTAGACAGAAACCTGAATCT GTTGACTCGGAGGAGCCCATTCTCT), cyclin B2 (AGA GCTGAGGGTTCTCCCAATCTTCGTTATCAATGTCCTC GATTTTGCAG), cyclin D3(GAGTGCTGGTCTGGCTGGG CCCTTGGCTGCTGGAGCCCCGGGGGGCTTTG) and the rRNA 18S (Gorospe et al., 1996) were 3 0 end-labelled using terminal transferase and [a-32 P]dATP. PCR-generated fragments of cyclin A and cyclin B1 coding regions as well as a plasmid insert containing the cdk4 coding region (Gorospe et al., 1996) were labelled using random primers, Klenow enzyme and [a-32 P]dATP. Signals on Northern blots were visualized and quantitated with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA) and 18S signals were used to normalize for differences in sample loading and transfer.
